Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology & Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for NEK7 drug discovery. The table below catalogs products and network targets to support drug discovery workflows.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NEK7 Full-Length / Kinase Domain Protein (High purity >95%, Endotoxin <1EU/ug, Sequence Verified, ATP-binding site intact) | View NEK7 Products |
| Gene Delivery | NEK7 Lentivirus Premade Particles (Full-length ORF, high titer >1E8 TU/ml, for stable cell line construction) | View NEK7 Products |
| Benchmark Ab | Anti-NEK7 Monoclonal Antibody (Recombinant, sequence-verified positive control for Western/ELISA) | View NEK7 Products |
| Validator | NEK7 siRNA Set (3 target-specific + 1 scrambled, for knockdown verification and assay specificity controls) | View NEK7 Products |
| Related Target A | NEK6 – Closest paralogue; essential for kinase selectivity profiling and family off-target assessment | View NEK6 Products |
| Related Target B | NLRP3 – Essential binding partner for inflammasome activation; functional pathway partner | View NLRP3 Products |
| Related Target C | NEK9 – Upstream activator kinase; critical for phosphorylation cascade studies | View NEK9 Products |
| Related Target D | IL-1beta (IL1B) – Downstream effector of the NEK7-NLRP3 pathway | View IL1B Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| NEK Family Selectivity Screening (NEK6/NEK9 cross-reactivity) | NEK Family Panel (NEK1/2/6/7/9) available with >95% purity; sequence-verified ATP-binding domains for accurate SAR. Homolog proteins strictly verified by mass spec and Theoretical MW. |
| Protein-Protein Interaction (PPI) Validation (NEK7-NLRP3 binding) | High purity (>95%) full-length NEK7 preserving native folding; sequence verified by mass spec. Suitable for TR-FRET, SPR, and co-IP. |
| Drug Resistance Profiling | Gatekeeper Mutant Proteins (e.g., T158M analogs) for resistance mechanism studies; Theoretical MW confirmed by mass spec. |
| Cellular Target Engagement & Overexpression | Lentivirus-ORF for stable overexpression lines; Endotoxin-controlled (<1EU/ug) for sensitive cell assays. |
| Lack of Robust Controls | Recombinant positive control antibodies included for western blot and assay standardization. |
| Target Validation False Positives | Validated siRNA included for knockdown confirmation; eliminates false positives in screening cascades. |
Live NEK7 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Kinase Inhibitor Research
- ➤ Recent Patent Filings
- ➤ Latest Resistance Research
Global Clinical Landscape & Future Outlook
The race for NEK7 therapeutics is intensifying, with major players shifting focus from direct NLRP3 inhibition to NEK7 as a strategic upstream modulator. As first-generation inflammasome therapies face challenges with structural complexity and resistance (and first-generation ATP-competitive inhibitors enter preclinical development), the next wave of R&D is targeting the specific protein-protein interaction (PPI) interface between NEK7 and NLRP3, as well as allosteric sites and PROTAC-based degradation strategies to overcome kinase family selectivity challenges. This unique mechanism offers immense potential for treating severe inflammatory diseases (e.g., NASH, Alzheimer's, IBD) and oncology, without broadly compromising essential kinase activity or causing mitotic toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors (ATP-competitive) | Inflammasome Biotechs, Academic Consortia | Autoimmune, NASH, Gout, Solid Tumors | Kinase Selectivity Panel (Need high-purity NEK6/NEK2 counter-screen proteins) |
| PPI Inhibitors (Allosteric) | Academic & Preclinical Startups, Structure-based Drug Design Groups | Alzheimer's Disease, IBD, Neuroinflammation | Binding Assay (Need sequence-verified full-length NEK7 & NLRP3; conformation-specific mutant panel for mechanism validation) |
| PROTACs | Emerging Targeted Degradation Companies | Oncology, Severe Inflammation, Inflammatory Diseases | Degradation Assays (Need full-length NEK7 for ternary complex formation; stable cell lines via lentivirus) |
| siRNA Therapy | Oligonucleotide Platforms | NLRP3-driven Diseases | Knockdown Efficiency Validation (Need validated siRNA controls) |
NEK7 Molecular Differentiation & Assay Strategy
Critical differentiation factors for best-in-class NEK7 drugs include: (1) Mechanism of binding – ATP-competitive vs. allosteric PPI inhibition; (2) Subfamily selectivity – must avoid cross-reactivity with NEK6 (~85% kinase domain identity) to prevent cardiac or mitotic side effects; (3) Functional separation – drug must block NLRP3-mediated IL-1β release without affecting NEK7's mitotic function. TarMart supports these needs with high-purity full-length proteins (native conformation for PPI assays), NEK family selectivity panels (including NEK1/2/6/7/9), gatekeeper mutant proteins (e.g., T158M for resistance studies), lentivirus for stable cell lines, and validated siRNA for target engagement. Known NEK7 mutations include rs55833332 (dbSNP) and a somatic mutation found in ovarian serous carcinoma (UniProt VAR_040925).